Cerenis Therapeutics receives €2.5 million investment from French government through OSEO
The financing will support continued development of the company's CER-001 program (recombinant HDL). In 2008 the company initiated preclinical studies to enable an Investigational New Drug (IND) application for this product candidate.
"This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development." said Jean-Louis Dasseux, Ph.D., M.B.A., president and CEO of Cerenis. "We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.